Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study

Author:

Guilleminault Laurent123ORCID,Camus Claire3,Raherison-Semjen Chantal34,Capdepon Audrey5,Bourdin Arnaud36,Bonniaud Philippe37,Fry Stéphanie38,Devouassoux Gilles39,Blanc François-Xavier310,Pison Christophe311,Dupin Clairelyne312,Khayath Naji313,Courdeau Joelle14,Valcke-Brossollet Judith15,Nocent-Ejnaini Cécilia16,Rolland Fabien17,Lamandi Carmen18,Proust Alain19,Ozier Anaig20,Portel Laurent21,Gaspard Wanda22,Roux-Claude Pauline323,Beurnier Antoine324,Martinez Stéphanie25,Dot Jean-Marc26,Hennegrave Florence27,Vignal Guillaume28,Auvray Etienne29,Paleiron Nicolas30,Just Nicolas31,Miltgen Jean32,Russier Maud33,Olivier Cécile34,Taillé Camille312,Didier Alain123

Affiliation:

1. Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France

2. Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Inserm U1291, University of Toulouse, CNRS U5282, Toulouse, France

3. CRISALIS/F-CRIN INSERM Network, Toulouse, France

4. University of French West Indies, Respiratory Diseases Department, Pointe -à Pitre, Guadeloupe

5. AstraZeneca, Paris, France

6. Respiratory Diseases Department, Montpellier University Hospital, Montpellier, France

7. Respiratory Diseases Department, Dijon University Hospital, Dijon, France

8. Respiratory Diseases Department, Lille University Hospital, Lille, France

9. Respiratory Diseases Department, Lyon University Hospital, HCL, Lyon, France

10. Nantes Université, CHU de Nantes, INSERM, Service de Pneumologie, CIC 1413, l’Institut du Thorax, Nantes, France

11. Respiratory Diseases Department, Grenoble University Hospital, Grenoble, France

12. Respiratory Diseases Department, Bichat Hospital, AP-HP, Paris, France

13. Respiratory Diseases Department, Strasbourg University Hospital, Strasbourg, France

14. Respiratory Diseases Department, Bigorre Hospital, Tarbes, France

15. Private practice in Armand Brillard Hospital, Nogent-sur-Marne, France

16. Respiratory Diseases Department, Côte-Basque Hospital, Bayonne, France

17. Respiratory Diseases Department, Cannes Hospital, Cannes, France

18. Respiratory Diseases Department, GHRMSA Hospital, Mulhouse, France

19. Respiratory Diseases Department, Nimes Hospital, Nîmes, France

20. Respiratory Diseases Department, Saint Augustin Clinic, Bordeaux, France

21. Respiratory Diseases Department, Libourne Hospital, Libourne, France

22. Respiratory Diseases Department, Army Training Hospital HIA Percy Clamart, Clamart, France

23. Respiratory Diseases Department, Jean Minjoz University Hospital, Besançon, France

24. Department of Physiology – Function Tests, DMU 5 Thorinno, twin-site Hôpital Bicêtre (Le Kremlin Bicêtre) and Ambroise Paré (Boulogne-Billancourt), AP-HP, Paris, France

25. Respiratory Diseases Department, Aix-en-Provence Hospital, Aix-en-Provence, France

26. Respiratory Diseases Department, Médipôle Hospital, Villeurbanne, France

27. Respiratory Diseases Department, Dunkerque Hospital, Dunkerque, France

28. Respiratory Diseases Department, Pau Hospital, Pau, France

29. Respiratory Diseases Department, Métropole Savoie Hospital, Chambéry, France

30. Respiratory Diseases Department, Army Training Hospital HIA Ste Anne Toulon, Toulon, France

31. Respiratory Diseases Department, Roubaix Hospital, Roubaix, France

32. Respiratory Diseases Department, Polyclinique Les Fleurs, Ollioules, France

33. Respiratory Diseases Department, Orléans Regional Hospital, Orléans, France

34. Respiratory Diseases Department, La Louvière Private Hospital, Lille, France

Abstract

Background: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. Purpose: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. Design: The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. Methods: Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. Results: The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. Conclusion: Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.

Funder

AstraZeneca France

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pulmonary and Respiratory Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3